10x Science built a platform that uses chemistry-based algorithms and AI agents to interpret complex mass spectrometry data, speeding up protein characterization for drug development. Backed by a $4.8 million seed round, it helps biotechs and pharma quickly validate AI-generated treatment candidates. The startup plans to refine its models and expand offerings by integrating broader cellular data.

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

Three MIT PhD students reverse-engineered Google's AlphaFold 3, creating Boltz-1 as an open-source alternative for drug discovery. Their platform enables pharmaceutical companies to conduct rapid and cost-effective drug-binding predictions while maintaining free access to the underlying models. Boltz aims to challenge commercial restrictions and offer a more accessible solution within the competitive landscape of AI in drug discovery.

Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.